AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
$100M in savings not enough to justify Intel’s coffee cut
2
ScaleOps raises $58M Series B as demand grows for cloud automation solutions
3
Why Monday.com’s impressive revenue jump wasn’t enough for Wall Street
4
Alison.ai closes $13.3M to scale AI-based video ads
5
Cyber startup Upwind raising $100 million at $850-900M valuation
More news

Kare Schultz

6 stories about Kare Schultz
מפעל טבע בקנדה

Closure of another criminal case will help Teva's new CEO to focus on return to growth

22.08.23|Sophie Shulman
The pharmaceutical company has reached a compromise after being suspected of price-fixing with other generic drug manufacturers in the US. In the first four years, it will pay $22.5 million and in 2028 - $135 million. In addition, the company will donate two drugs worth $50 million to humanitarian organizations
ריצ'רד פרנסיס מנכ"ל טבע החדש על רקע אתר חברת טבע בכפר סבא

Schultz kept Teva away from the abyss, but couldn't find a runway to growth

22.11.22|Sophie Shulman
Kare Schultz, who served as CEO of the pharmaceutical company for the past five years, has left the company a year early after amassing a salary of more than $100 million. His replacement, Richard Francis, is taking over with less debt and less legal issues, but with the big challenge of creating new growth engines
מפעל טבע טק נאות חובב פיטורים

Teva in talks with Covid-19 vaccine manufacturers to co-produce shots

10.02.21|Reuters and CTech
"We are positive towards contributing by manufacturing some of those vaccines that either have been approved or are just about to be approved," said CEO
קור שולץ מנכ"ל חברת טבע תרופות 23.8.20

Teva beats analysts predictions with increased revenues from growth drivers

10.02.21|Sophie Shulman
The Israeli pharmaceutical company concluded the quarter with $4.5 billion in revenues, bringing it to a total of $16.6 billion for 2020
מנכ"ל טבע החדש קור שולץ

Generic Drugmaker Teva Says Profit Will Continue to Drop in 2018

08.02.18|Dror Reich
Israel’s Teva reports a $17-billion goodwill impairment citing the decline of the U.S. generic market
מנכ"ל טבע החדש קור שולץ 2

New CEO to Break Teva’s Copaxone Habit

11.09.17|Sophie Shulman, Dror Reich
Troubled drugmaker says new CEO must work to quickly regain its financial credibility